Annual report pursuant to Section 13 and 15(d)

Geographic information

v3.24.0.1
Geographic information
12 Months Ended
Dec. 31, 2023
Geographic information  
Geographic information

Note 14 — Geographic information

Operations by geographic area

Revenue represents recognized income from the Astellas Collaboration Agreement, the Genentech Collaboration and License Agreement, the GSK Collaboration and License Agreement and the GSK Termination and Transfer Agreement. All revenue was derived in the United Kingdom.

Long-lived assets (excluding intangibles, deferred tax and financial instruments) were located as follows (in thousands):

December 31, 

December 31, 

    

2023

    

2022

U.K.

$

40,988

$

42,387

U.S.

 

30,720

 

29,148

Total long-lived assets(1)

$

71,708

$

71,535

Major customers:

During the year ended December 31, 2023, 73%, 26% and 1% of the Company’s revenues were generated from Astellas, Genentech and GSK, respectively.